Menu
Not yet recruiting NCT07529587

Laparoscopic Umbilico-uterine Trunk Clipping Approach in the Management of Enhanced Myometrial Vascularity

No phase Interventional Enhanced Myometrial Vascularity

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Laparoscopic Umbilico-uterine trunk Clipping Approach, Mirena Intrauterine Device Insertion.
Who it may be relevant to
Registry conditions: Enhanced Myometrial Vascularity. Basic parameters: 18 years — 45 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This study aims to address this knowledge gap by conducting a randomized active-controlled trial comparing laparoscopic umbilico-uterine trunk clipping with Mirena Intrauterine Device Insertion (an active treatment method chosen and justified based on current clinical practice) in reducing monthly menstrual blood loss in women with enhanced myometrial vascularity. By providing reliable data on clinical efficacy and patient-related outcomes, this study can contribute to guiding clinical decision-making and improving the care of women with this condition.

Interventions

  • Procedure Laparoscopic Umbilico-uterine trunk Clipping Approach
    1. Patient preparation. 2. Laparoscopic technique. 3. Identification and clipping of the umbilico-uterine trunk. 4. Post-operative care.
  • Procedure Mirena Intrauterine Device Insertion
    Mirena Intrauterine Device Insertion is considered the current standard of care or a relevant alternative

Primary outcome measures

  • monthly menstrual blood loss [Time frame: The change in PBAC score within 6 months after procedure]

Eligibility criteria

Inclusion criteria

  • Confirmed diagnosis of Enhanced Myometrial Vascularity.
  • Presence of clinical symptoms related to Enhanced Myometrial Vascularity: Such as menorrhagia affecting quality of life, or abnormal uterine bleeding (AUB) unresponsive to initial medical treatments.
  • Women of reproductive age (18-45 years).
  • Willingness to undergo surgical treatment: Participants must be willing to undergo one of the two surgical procedures under investigation (laparoscopic umbilico-uterine trunk clipping or Mirena Intrauterine Device Insertion).
  • Written informed consent: Participants must be able to understand the study information and provide written informed consent to participate.
  • Adequate general health to undergo anesthesia and laparoscopic surgery: This will be assessed by the responsible physician

Exclusion criteria

  • Presence of other known causes of menorrhagia or abnormal uterine bleeding: Such as large uterine fibroids (> 3 cm in diameter, or with a location causing distortion of the uterine cavity), large endometrial polyps, untreated endometrial hyperplasia, or known bleeding disorders.
  • History of extensive prior pelvic surgery: That may increase the difficulty or risks of laparoscopic surgery or significantly affect uterine blood supply.
  • Current pregnancy or suspicion of pregnancy: Pregnancy testing will be performed before enrollment.
  • Current breastfeeding.
  • Presence of contraindications to general anesthesia or laparoscopic surgery: This will be assessed by the anesthesiologist.
  • Severe, unstable systemic diseases: Such as uncontrolled cardiovascular disease, pulmonary disease, renal disease, or liver disease.
  • Receiving hormonal therapy that affects the menstrual cycle or uterine blood flow.
  • Participation in another clinical trial that could interfere with the outcomes of this study.
  • Inability to comply with study procedures or follow-up.
  • Any other condition that the principal investigator deems would compromise the safety of the participant or affect the study outcomes.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07529587 · 1647-8-2025

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗